Imlifidase denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for imlifidase are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Imposed Quantity Limits on Imlifidase — and How to Appeal

Imlifidase is administered in a highly specific, protocol-driven way in the transplant setting. Aetna's quantity limit denial means that the amount requested — the number of vials, doses, or treatment cycles — exceeds what Aetna's coverage policy allows without additional review. This type of denial is common for high-cost specialty agents and does not mean the drug itself is non-covered; it means the quantity requires further justification.

## Why This Denial Is Appealable

Quantity-limit denials are among the most successfully overturned on appeal when the prescriber documents the clinical rationale for the requested amount. The key is to show that the quantity requested is consistent with the FDA-approved prescribing information, the treating institution's protocol, and the applicable transplant medicine society guidelines — and that it reflects your patient's specific clinical situation, not a generic request. Under ERISA §503 and ACA §2719, you have the right to a full internal appeal and, if necessary, independent external review.

## Federal Appeal Framework

• Internal appeal: Submit within the deadline on the denial notice (typically 180 days for standard pre-service denials). Aetna must decide within 30 days for prospective (pre-service) reviews.
• Expedited review: Request expedited internal review if the transplant is time-sensitive; Aetna must respond within 72 hours.
• External review: If the internal appeal is denied, you may proceed to independent external review. An external reviewer with transplant medicine expertise will evaluate whether Aetna's quantity limit was clinically appropriate.
• State insurance department: File a parallel complaint if you believe Aetna's policy is inconsistent with your state's coverage mandates.

## Documentation to Gather

• Prescriber letter with quantity justification: The transplant physician must explain the number of doses requested, citing the FDA-approved prescribing information (not a paraphrase — attach the relevant section of the label) and any applicable transplant society dosing guidance.
• Institutional protocol: If the transplant center uses an established desensitization protocol, include it. Aetna reviewers give significant weight to protocol-based requests from accredited transplant centers.
• Diagnosis and clinical context: Documentation showing the patient's specific sensitization profile and why a particular treatment course is required.
• Aetna clinical policy bulletin (CPB): Request the exact CPB and its quantity limit rationale. Your appeal must address each limit criterion individually.
• Prior authorization history: If prior doses were approved, include that approval history as context.

## Criteria-Mapping Structure

Map each quantity-limit criterion from Aetna's CPB to a specific piece of documentation:

| Aetna Quantity Criterion | Supporting Evidence | |---|---| | Approved dosing per FDA label | Relevant label section attached | | Quantity consistent with protocol | Institutional protocol document | | Clinical necessity for requested amount | Prescriber letter with patient-specific rationale | | No duplication with other covered agents | Prescriber confirmation |

A prescriber-signed letter that explains quantity in clinical — not just administrative — terms is the single most effective document in a quantity-limit appeal.